MX2022003739A - Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros. - Google Patents

Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros.

Info

Publication number
MX2022003739A
MX2022003739A MX2022003739A MX2022003739A MX2022003739A MX 2022003739 A MX2022003739 A MX 2022003739A MX 2022003739 A MX2022003739 A MX 2022003739A MX 2022003739 A MX2022003739 A MX 2022003739A MX 2022003739 A MX2022003739 A MX 2022003739A
Authority
MX
Mexico
Prior art keywords
pla2
treatment
pathological conditions
kidney injury
acute kidney
Prior art date
Application number
MX2022003739A
Other languages
English (en)
Inventor
Matthew R Lewin
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of MX2022003739A publication Critical patent/MX2022003739A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan métodos para el tratamiento de condiciones patológicas que causan hemólisis, edema cerebral, daño renal agudo y choque no anafiláctico, incluyendo envenenamiento, trauma, malaria cerebral y enfermedades mastocitarias usando al menos un inhibidor de PLA, sólo o en combinación con otros agentes. La versatilidad inesperada de los inhibidores de PLA, sus formas de dosificación y combinaciones los hacen candidatos como medicinas esenciales para el mundo en desarrollo.
MX2022003739A 2016-04-29 2018-10-25 Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros. MX2022003739A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329611P 2016-04-29 2016-04-29
US201662340075P 2016-05-23 2016-05-23
US201662423693P 2016-11-17 2016-11-17

Publications (1)

Publication Number Publication Date
MX2022003739A true MX2022003739A (es) 2022-05-02

Family

ID=60161200

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013084A MX2018013084A (es) 2016-04-29 2017-05-01 Inhibidores de pla2 y hem-coa para el tratamiento de condiciones patológicas que causan hemólisis, edema cerebral y daño renal agudo.
MX2022003739A MX2022003739A (es) 2016-04-29 2018-10-25 Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013084A MX2018013084A (es) 2016-04-29 2017-05-01 Inhibidores de pla2 y hem-coa para el tratamiento de condiciones patológicas que causan hemólisis, edema cerebral y daño renal agudo.

Country Status (10)

Country Link
US (1) US20210220332A1 (es)
EP (1) EP3448378B1 (es)
JP (2) JP2019514935A (es)
KR (2) KR20230049762A (es)
CN (2) CN116585306A (es)
AU (2) AU2017257185B8 (es)
CA (1) CA3022013A1 (es)
IL (2) IL307232A (es)
MX (2) MX2018013084A (es)
WO (1) WO2017190141A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210220332A1 (en) * 2016-04-29 2021-07-22 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
WO2023086343A1 (en) * 2021-11-09 2023-05-19 Ophirex, Inc. Compositions and dosage forms for topical and transdermal delivery of actives and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
EP1667727B1 (en) * 2003-09-09 2008-07-09 University of Florida Research Foundation, Inc. Polyamine-metal chelator conjugates
FR2873293B1 (fr) 2004-07-21 2006-11-17 Cerep Sa Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin
RU2007143040A (ru) * 2005-04-21 2009-05-27 Гленн А. ГОЛДШТЕЙН (US) Амид n-ацетилцистеина (амид nac) в лечении заболеваний и состояний, связанных с окислительным стрессом
WO2010081022A1 (en) * 2009-01-08 2010-07-15 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
US20110269786A1 (en) * 2010-04-30 2011-11-03 Colin Hislop Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20140087003A1 (en) * 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US20210220332A1 (en) * 2016-04-29 2021-07-22 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury

Also Published As

Publication number Publication date
KR20230049762A (ko) 2023-04-13
AU2017257185B9 (en) 2023-07-06
JP2019514935A (ja) 2019-06-06
CN109562098A (zh) 2019-04-02
AU2023233187A1 (en) 2023-10-12
IL262620A (en) 2018-12-31
AU2017257185B2 (en) 2023-06-22
IL262620B2 (en) 2024-02-01
KR20190005898A (ko) 2019-01-16
BR112018072162A2 (pt) 2019-02-12
WO2017190141A1 (en) 2017-11-02
CN116585306A (zh) 2023-08-15
JP2022177020A (ja) 2022-11-30
IL307232A (en) 2023-11-01
IL262620B1 (en) 2023-10-01
EP3448378A1 (en) 2019-03-06
MX2018013084A (es) 2019-03-06
US20210220332A1 (en) 2021-07-22
EP3448378B1 (en) 2024-04-17
CA3022013A1 (en) 2017-11-02
AU2017257185A1 (en) 2018-11-22
AU2017257185B8 (en) 2023-07-06
EP3448378A4 (en) 2020-04-08
CN109562098B (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
MX2022003895A (es) Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
EA201992546A1 (ru) Средства на основе антител к cd33
EA201790806A1 (ru) Иммунорегулирующие средства
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
WO2015173633A3 (en) Hdl therapy markers
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12018501443A1 (en) Methods of administering hepcidin
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201792610A1 (ru) Способ лечения неврологического заболевания
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX2022003739A (es) Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1